CJC-1295 DAC

Compound Profile

CJC-1295 DAC is reviewed here for growth-hormone signaling and recovery context.

Research Summary

Evidence Strength Very limited

Primary Evidence

Safety notices, literature searches, limited protocol data

Research Focus

Growth-hormone signaling, Recovery, Body composition

Mechanism

Target context: GHRH

Long-Term Data

Limited, unclear, or affected by safety flags.

Current Consensus

Claims need extra caution because evidence is thin or safety flags apply.

Route(s) Subcutaneous

Typical dose 300 mcg

Dosing window Anytime

Receptor / target GHRH

Properties GH Secretagogue

Pre-mixed No

How CJC-1295 works in the body

CJC-1295 is discussed through the growth-hormone pathway: GHRH-style signaling, pituitary response, liver IGF-1, and downstream muscle context. Tap a glowing point to see the pathway.

This is here to help you learn and is not medical advice. Evidence labels show how much human research stands behind each effect.

Protocols

Protocol logic check

Medical literature and study context

Independent evidence

Regulatory status: unapproved or compounded peptide with FDA safety risk flag

Storage

No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.

• Active cancer or history of malignancy: sustained GH and IGF-1 elevation accelerates cell proliferation; contraindicated in any actively growing tumor.
• High risk of tumor growth: subjects with pre-cancerous conditions or elevated cancer biomarkers.
• Active acromegaly or conditions involving excess endogenous GH or IGF-1: additive hypersomatotrophism.
• Uncontrolled diabetes mellitus or significant insulin resistance: continuous GH elevation meaningfully increases insulin resistance; DAC's persistent hormonal profile is more problematic than pulsatile approaches.
• Diabetic ketoacidosis.
• Disruption of the hypothalamic-pituitary axis: pituitary adenoma, cranial radiation history, or post-surgical pituitary dysfunction.
• Concurrent use with CJC-1295 No DAC, sermorelin, tesamorelin, or HGH 191aa: direct GHRH receptor competition or redundant GH axis overstimulation.
• Concomitant high-dose glucocorticoid therapy: blunts pituitary GH response and inhibits IGF-1.
• Severe carpal tunnel syndrome: GH-mediated fluid retention worsens median nerve compression.
• Pregnancy: safety not established.
• Breastfeeding: safety not established.
• Known hypersensitivity to CJC-1295 DAC or any formulation excipients.
• Pediatric use in children with closed growth plates.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.

• Water retention and peripheral edema: the most frequently reported adverse effect; GH-mediated sodium and fluid retention is more persistent and pronounced with DAC than with No DAC due to continuous GH elevation.
• Head rush and transient facial flushing: present but typically milder than with No DAC due to the absence of a sharp GH peak.
• Joint stiffness and arthralgia: GH-mediated periarticular fluid accumulation; common, particularly in wrists, hands, and knees.
• Tingling or numbness in extremities (paresthesia): from GH-related fluid shifts compressing peripheral nerves.
• Carpal tunnel syndrome: sustained GH elevation can produce or exacerbate median nerve compression.
• Fatigue or lethargy: more diffuse than with No DAC; related to sustained rather than pulsatile GH effects.
• Headache: less acute than No DAC but present.
• Increased appetite: modest orexigenic GH effects.
• Vivid dreams: GH elevation during sleep phases.
• Insulin resistance: continuous rather than pulsatile GH exposure has more significant impact on insulin sensitivity; monitor fasting glucose, particularly in subjects with metabolic risk factors.
• Elevated fasting blood glucose: secondary to GH-mediated insulin resistance; monitor throughout cycle.
• Pituitary downregulation: risk with DAC is somewhat higher than No DAC due to continuous GHRH-R stimulation; strict 4-week washout is required.
• Slow side effect clearance post-cycle: albumin-bound DAC depot persists for 2+ weeks after the last injection; side effects do not resolve immediately upon stopping.
• Injection site irritation: localized redness, swelling, or discomfort.
• Antibody formation: rare; small percentage of subjects may develop anti-peptide antibodies with long-cycle use.

Compatibility

The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

Sources

• FDA drug/regulatory guidance
• FDA bulk-substance safety risk page
• PubMed literature search: CJC-1295 DAC
• ClinicalTrials.gov study records: CJC-1295 DAC